Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP

Apis Capital Advisors LLC raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 28.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,000 shares of the specialty pharmaceutical company’s stock after buying an additional 36,000 shares during the period. ANI Pharmaceuticals comprises approximately 3.3% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 14th biggest position. Apis Capital Advisors LLC owned 0.76% of ANI Pharmaceuticals worth $15,022,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. UBS Group AG raised its holdings in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Rubric Capital Management LP boosted its holdings in ANI Pharmaceuticals by 33.3% during the 3rd quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after acquiring an additional 85,745 shares during the period. Balyasny Asset Management L.P. boosted its holdings in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares during the period. Finally, Loomis Sayles & Co. L P grew its position in ANI Pharmaceuticals by 6.4% in the 2nd quarter. Loomis Sayles & Co. L P now owns 206,382 shares of the specialty pharmaceutical company’s stock valued at $13,466,000 after acquiring an additional 12,494 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
• Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn’t itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
• Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
• Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

Wall Street Analyst Weigh In

A number of analysts have weighed in on ANIP shares. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Barclays began coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Finally, Guggenheim lifted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Insider Buying and Selling

In related news, insider Christopher Mutz sold 5,323 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $78.02, for a total value of $415,300.46. Following the completion of the transaction, the insider owned 84,840 shares in the company, valued at $6,619,216.80. This trade represents a 5.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $77.53, for a total value of $161,572.52. Following the sale, the senior vice president directly owned 50,993 shares of the company’s stock, valued at approximately $3,953,487.29. This represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,482 shares of company stock worth $2,248,424 over the last three months. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Down 2.8%

NASDAQ:ANIP opened at $70.49 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The company has a market cap of $1.58 billion, a PE ratio of 20.98 and a beta of 0.52. The company’s 50 day moving average is $79.12 and its two-hundred day moving average is $85.30.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.